Clinical trial of anivamersen-pegnivacogin [REG2] for sub-acute venous thrombosis indications

Trial Profile

Clinical trial of anivamersen-pegnivacogin [REG2] for sub-acute venous thrombosis indications

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Feb 2014

At a glance

  • Drugs Anivamersen-pegnivacogin (Primary)
  • Indications Venous thrombosis
  • Focus Adverse reactions
  • Sponsors Regado Biosciences
  • Most Recent Events

    • 19 Feb 2014 New trial record
    • 13 Feb 2014 The US FDA has accepted an IND for further clinical development of REG2 in sub-acute venous thrombosis indications, according to a Regado Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top